VXL — Vaxil Bio Income Statement
0.000.00%
Last trade - 00:00- CA$0.52m
- CA$0.17m
- 42
- 63
- 13
- 32
Annual income statement for Vaxil Bio, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.35 | 0.986 | 0.584 | 0.254 | 0.196 |
| Operating Profit | -1.35 | -0.986 | -0.584 | -0.254 | -0.196 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.36 | -0.986 | -0.584 | -0.254 | -0.178 |
| Net Income After Taxes | -1.36 | -0.986 | -0.584 | -0.254 | -0.178 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.36 | -0.986 | -0.584 | -0.254 | -0.178 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.36 | -0.986 | -0.584 | -0.254 | -0.178 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.667 | -0.362 | -0.213 | -0.095 | -0.065 |